SphK2 over-expression promotes osteosarcoma cell growth

It is needed to explore novel biological markers for early diagnosis and treatment of human osteosarcoma. Sphingosine kinase 2 (SphK2) expression and potential functions in osteosarcoma were studied. We demonstrate that SphK2 is over-expressed in multiple human osteosarcoma tissues and established human osteosarcoma cell lines. Silence of SphK2 by targeted-shRNAs inhibited osteosarcoma cell growth, and induced cell apoptosis. On the other hand, exogenous over-expression of SphK2 could further promote osteosarcoma cell growth. Notably, microRNA-19a-3p (“miR-19a-3p”) targets the 3′ UTR (untranslated region) of SphK2 mRNA. Remarkably, forced-expression of miR-19a-3p silenced SphK2 and inhibited osteosarcoma cell growth. In vivo, SphK2 silence, by targeted-shRNA or miR-19a-3p, inhibited U2OS tumor growth in nude mice. These results suggest that SphK2 could be a novel and key oncotarget protein for OS cell progression.

[1]  Xiao-zhong Zhou,et al.  Identification of DNA-PKcs as a primary resistance factor of salinomycin in osteosarcoma cells , 2016, Oncotarget.

[2]  H. Yi,et al.  miR-135b expression downregulates Ppm1e to activate AMPK signaling and protect osteoblastic cells from dexamethasone , 2016, Oncotarget.

[3]  Q. Jiang,et al.  SC79 protects retinal pigment epithelium cells from UV radiation via activating Akt-Nrf2 signaling , 2016, Oncotarget.

[4]  Chen Yao,et al.  The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models , 2016, Oncotarget.

[5]  W. Liu,et al.  Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer , 2016, Tumor Biology.

[6]  Michael W. Bishop,et al.  Future directions in the treatment of osteosarcoma , 2016, Current opinion in pediatrics.

[7]  S. Ferrari,et al.  An update on chemotherapy for osteosarcoma , 2015, Expert opinion on pharmacotherapy.

[8]  L. Ricci-Vitiani,et al.  miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal , 2015, Oncotarget.

[9]  L. Qi,et al.  Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo , 2015, Journal of experimental & clinical cancer research : CR.

[10]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Anders Kolb,et al.  MicroRNAs and Potential Targets in Osteosarcoma: Review , 2015, Front. Pediatr..

[12]  E. Izaurralde,et al.  Towards a molecular understanding of microRNA-mediated gene silencing , 2015, Nature Reviews Genetics.

[13]  K. Mimori,et al.  Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer , 2015, British Journal of Cancer.

[14]  C. Xie,et al.  ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer , 2015, Cancer biology & therapy.

[15]  Stephen A. Goutman,et al.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era , 2015, Nature Reviews Neurology.

[16]  Yiming Li,et al.  Dexamethasone-induced apoptosis of osteocytic and osteoblastic cells is mediated by TAK1 activation. , 2015, Biochemical and biophysical research communications.

[17]  Min Wei,et al.  MicroRNA-144 suppresses osteosarcoma growth and metastasis by targeting ROCK1 and ROCK2 , 2015, Oncotarget.

[18]  Feng Zhou,et al.  Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma , 2015, Cancer biology & therapy.

[19]  David M. Thomas,et al.  Translational biology of osteosarcoma , 2014, Nature Reviews Cancer.

[20]  Jiexiong Feng,et al.  Review of the molecular pathogenesis of osteosarcoma. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[21]  T. Stopka,et al.  Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum , 2014, BMC Cancer.

[22]  J. Yang,et al.  MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene , 2014, Oncogene.

[23]  C. Wallington-Beddoe,et al.  Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. , 2014, Cancer research.

[24]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[25]  Q. Wu,et al.  MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1 , 2014, Cell Death and Disease.

[26]  M. Burow,et al.  Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival , 2014, Pharmacological reports : PR.

[27]  Qiu-lin Tang,et al.  Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[28]  S. Milstien,et al.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond , 2013, Nature Reviews Drug Discovery.

[29]  B. Wang,et al.  Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. , 2013, Biochemical and biophysical research communications.

[30]  Wei Zhang,et al.  New molecular insights into osteosarcoma targeted therapy , 2013, Current opinion in oncology.

[31]  Y. Peterson,et al.  Characterization of Isoenzyme-Selective Inhibitors of Human Sphingosine Kinases , 2012, PloS one.

[32]  L. Obeid,et al.  Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. , 2012, Anti-cancer agents in medicinal chemistry.

[33]  A. Pasquinelli.  MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship , 2012, Nature Reviews Genetics.

[34]  S. Milstien,et al.  Targeting sphingosine-1-phosphate in hematologic malignancies. , 2011, Anti-cancer agents in medicinal chemistry.

[35]  Charles D Smith,et al.  Ablation of Sphingosine Kinase-2 Inhibits Tumor Cell Proliferation and Migration , 2011, Molecular Cancer Research.

[36]  Steven Elliott,et al.  Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2 , 2011, Cancer biology & therapy.

[37]  L. Rhodes,et al.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. , 2010, Endocrinology.

[38]  Deepak Poudyal,et al.  Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase. , 2010, Carcinogenesis.

[39]  Y. Zhuang,et al.  Pharmacology and Antitumor Activity of ABC294640, a Selective Inhibitor of Sphingosine Kinase-2 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[40]  B. Brüne,et al.  Sphingosine kinase 2 deficient tumor xenografts show impaired growth and fail to polarize macrophages towards an anti‐inflammatory phenotype , 2009, International journal of cancer.

[41]  J. Gamble,et al.  The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? , 2008, Biochimica et biophysica acta.

[42]  S. Milstien,et al.  Targeting SphK1 as a new strategy against cancer. , 2008, Current drug targets.

[43]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[44]  S. Bielack,et al.  Current strategies of chemotherapy in osteosarcoma , 2006, International Orthopaedics.

[45]  R. Gorlick,et al.  Chemotherapy resistance in osteosarcoma: current challenges and future directions , 2006, Expert review of anticancer therapy.

[46]  J. M. Soriano,et al.  Mechanism of action of sphingolipids and their metabolites in the toxicity of fumonisin B1. , 2005, Progress in lipid research.

[47]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[48]  S. Payne,et al.  Sphingosine Kinase Type 2 Is a Putative BH3-only Protein That Induces Apoptosis* , 2003, Journal of Biological Chemistry.

[49]  M. Maceyka,et al.  Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. , 2002, Biochimica et biophysica acta.

[50]  A. Davis,et al.  Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A Krishan,et al.  Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. , 2001, Journal of immunological methods.

[52]  S. Ben‐Sasson,et al.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation , 1992, The Journal of cell biology.

[53]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[54]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[55]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[56]  Maryam K. Mohammed,et al.  Molecular pathogenesis and therapeutic strategies of human osteosarcoma. , 2015, Journal of biomedical research.

[57]  L. Ricci-Vitiani,et al.  miR-135 b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation , migration and self-renewal , 2015 .

[58]  T. Goldkorn,et al.  Lung cancer and lung injury: the dual role of ceramide. , 2013, Handbook of experimental pharmacology.

[59]  Sarah Spiegel,et al.  Sphingosine-1-phosphate signaling and its role in disease. , 2012, Trends in cell biology.

[60]  W. Santos,et al.  Design, synthesis and biological activity of sphingosine kinase 2 selective inhibitors. , 2012, Bioorganic & medicinal chemistry.

[61]  M. Xiao,et al.  Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. , 2012, Experimental cell research.

[62]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.